Obviously, one may find weak points in almost every study like I did for Gotzsche and Johansen provocative review posted by Dew (#msg-52075086). I have posted the Stockley et al work to show the other side of the debate on augmentation therapy in alfa-1 antitrypsin deficiency. Bear in mind that all three sponsors of U.S. licensed Alpha-1-PI products have been asked to conduct post-marketing studies to help evaluate efficacy in terms of clinically meaningful endpoints directly related to emphysema. I think these placebo controlled trials focusing on lung CT scanning as an endpoint are important (because it might be a much better way of looking at efficacy in patient who have Alpha-1-antitrypsin deficiency), even if the sponsor is Talecris or CSL Behring and btw, the authors/investigators of all studies stated these relations so the possible conflicts of interest is well understood.
Market Data 
Markets 
AI
